Bicycle Therapeutics (BCYC) Competitors $8.76 0.00 (0.00%) As of 10:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. MIRM, ARWR, NAMS, RXRX, KNSA, VCEL, GMTX, DNLI, CGON, and HRMYShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Gemini Therapeutics (GMTX), Denali Therapeutics (DNLI), CG Oncology (CGON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors Mirum Pharmaceuticals Arrowhead Pharmaceuticals NewAmsterdam Pharma Recursion Pharmaceuticals Kiniksa Pharmaceuticals Vericel Gemini Therapeutics Denali Therapeutics CG Oncology Harmony Biosciences Mirum Pharmaceuticals (NASDAQ:MIRM) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings. Do analysts prefer MIRM or BCYC? Mirum Pharmaceuticals presently has a consensus target price of $60.73, suggesting a potential upside of 26.52%. Bicycle Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 193.43%. Given Bicycle Therapeutics' higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has more risk & volatility, MIRM or BCYC? Mirum Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Is MIRM or BCYC more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% Bicycle Therapeutics -450.64%-27.35%-20.81% Do institutionals and insiders believe in MIRM or BCYC? 86.2% of Bicycle Therapeutics shares are held by institutional investors. 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor MIRM or BCYC? Bicycle Therapeutics received 10 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 76.40% of users gave Mirum Pharmaceuticals an outperform vote while only 70.53% of users gave Bicycle Therapeutics an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13676.40% Underperform Votes4223.60% Bicycle TherapeuticsOutperform Votes14670.53% Underperform Votes6129.47% Which has better earnings & valuation, MIRM or BCYC? Mirum Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$379.25M6.27-$163.41M-$1.61-29.81Bicycle Therapeutics$25.72M22.94-$180.66M-$3.14-2.71 Does the media prefer MIRM or BCYC? In the previous week, Bicycle Therapeutics had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 11 mentions for Bicycle Therapeutics and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.79 beat Bicycle Therapeutics' score of 0.53 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals beats Bicycle Therapeutics on 10 of the 19 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$590.04M$6.91B$5.59B$8.59BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.598.8127.1220.00Price / Sales22.94254.61419.48155.53Price / CashN/A65.8538.2534.64Price / Book0.696.567.104.69Net Income-$180.66M$143.93M$3.23B$247.88M7 Day Performance0.24%3.35%2.45%2.34%1 Month Performance-0.93%10.64%8.65%6.06%1 Year Performance-65.18%3.73%31.26%13.59% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.3664 of 5 stars$8.76flat$25.00+185.4%-63.1%$606.67M$25.72M-2.66240News CoverageAnalyst RevisionMIRMMirum Pharmaceuticals3.2206 of 5 stars$47.05+1.4%$60.73+29.1%+85.0%$2.33B$379.25M-23.29140Analyst RevisionARWRArrowhead Pharmaceuticals3.6107 of 5 stars$16.57-1.4%$43.71+163.8%-32.1%$2.29B$545.21M-3.21400Analyst RevisionNAMSNewAmsterdam Pharma2.9925 of 5 stars$20.16+0.1%$42.86+112.6%+3.2%$2.26B$47.14M-10.724Trending NewsAnalyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals1.9308 of 5 stars$5.37-2.2%$7.60+41.5%-37.1%$2.23B$59.82M-3.51400Gap DownHigh Trading VolumeKNSAKiniksa Pharmaceuticals3.2592 of 5 stars$30.33+0.3%$38.80+27.9%+61.1%$2.21B$481.17M-216.63220Trending NewsInsider TradeVCELVericel2.6777 of 5 stars$43.82+1.2%$61.14+39.5%+2.0%$2.21B$238.54M730.46300Positive NewsGMTXGemini TherapeuticsN/A$50.02+4.2%N/A+33.6%$2.17BN/A-50.0230DNLIDenali Therapeutics4.354 of 5 stars$14.65-0.3%$33.71+130.1%-29.7%$2.13B$330.53M-5.31430Positive NewsAnalyst RevisionCGONCG Oncology2.5187 of 5 stars$27.00+0.3%$58.22+115.6%-25.6%$2.06B$662K-17.8861Positive NewsAnalyst RevisionHRMYHarmony Biosciences4.7782 of 5 stars$35.42-0.5%$53.00+49.6%+18.4%$2.03B$744.85M16.79200Positive NewsShort Interest ↑Analyst Revision Related Companies and Tools Related Companies Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Recursion Pharmaceuticals Competitors Kiniksa Pharmaceuticals Competitors Vericel Competitors Gemini Therapeutics Competitors Denali Therapeutics Competitors CG Oncology Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCYC Stock Free BCYC Stock Alerts